Attributes of pathological fractures in a Nigerian myeloma cohort

Submitted: 1 September 2024
Accepted: 17 September 2024
Published: 19 September 2024
Abstract Views: 129
PDF: 32
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Multiple Myeloma (MM) is a plasma cell tumor usually characterized by lytic bone lesions. Pathological Fracture (PF) is a debilitating condition that usually affects a patient’s psychomotor functions, treatment modality, morbidity, and outcome. We evaluated the associations, characteristics, and impact of PF on survival in a group of Nigerian myeloma cohort.  A 10-year (2011-2021) retrospective review of MM data from Nigerian tertiary hospital haemato-oncology unit to evaluate attributes of PFs in myeloma cohort.

Sixty-six patients had MM of which 23 had PF while forty-three had no fractures. Of the number with PF, 18 had lytic bone lesions, while 20 had bone pains. Monoclonal Immunoglobulin G was predominant followed by Immunoglobulin A. Significant correlations existed between hemoglobin level (r=0.446, p=0.002); platelet count (r=-0.347, p=0.041), serum calcium (r=0.471, p=0.006) and bone pains; as well as between urea level (r=-0.787, p=001), creatinine level (r=-0.853, p=0.001) and renal impairment respectively. PFs are associated with diabetes, peptic ulcer disease, hypertension, nephropathy, and arthritis. Bortezomib-based regimen was the choice treatment. Overall survival was 16 (69.6%) with 7 (30.4%) mortality.

PF is common amongst the myeloma cohort with the spine being the most common site. It is associated with significant comorbidities like hypertension, diabetes, peptic ulcer disease, and paraplegia and is characterized by severe debilitating bone pains, anemia, hypercalcemia, raised plasma monoclonal immunoglobulin, renal impairment, loss of man-hour at work, and psychosocial imbalance. The impact of the fracture has increased morbidity and mortality and has reduced the median survival duration to as low as 4 years.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Kazandjian D, Mailankody S, Korde N, Landgren O. Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. Clinical Advances in Hematology & Oncology. 2014;12:578-87.
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046-60. DOI: https://doi.org/10.1056/NEJMra1011442
Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443-59. DOI: https://doi.org/10.3322/caac.21357
Terpos E, Berenson J, Raje N, et al. Management of bone disease in multiple myeloma. Expert Rev Hematol. 2014;7:113-25. DOI: https://doi.org/10.1586/17474086.2013.874943
Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol. 1998;103:902-10. DOI: https://doi.org/10.1046/j.1365-2141.1998.01082.x
Menssen HD, Sakalova A, Fontana A, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002;20; 2353-9. DOI: https://doi.org/10.1200/JCO.2002.02.032
Xiao W, Wang Y, Pacios S, et al. Cellular and molecular aspects of bone remodeling. Front. Oral. Biol. 2016;18:9-16. DOI: https://doi.org/10.1159/000351895
Walker, RE, Lawson, MA, Buckle CH, et al. Myeloma bone disease: pathogenesis, current treatments and future targets. British Medical Bulletin. 2014;111:117-38. DOI: https://doi.org/10.1093/bmb/ldu016
Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16:1223-31. DOI: https://doi.org/10.1093/annonc/mdi235
Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473;139-46. DOI: https://doi.org/10.1016/j.abb.2008.03.018
Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA. 2001;98:11581-6. DOI: https://doi.org/10.1073/pnas.201394498
Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102:1064-9. DOI: https://doi.org/10.1182/blood-2003-02-0380
Melton LJ, Kyle RA, Achenbach SJ, et al. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20:487-93. DOI: https://doi.org/10.1359/JBMR.041131
Yong M, Jensen AÖ, Jacobsen JB, et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011;129:495-503. DOI: https://doi.org/10.1007/s10549-011-1475-5
Thorsteinsdottir S, Gislason G, Aspelund T, et al. Fractures and survival in multiple myeloma: results from a population-based study. Haematologica. 2020;105:1067-73. DOI: https://doi.org/10.3324/haematol.2019.230011
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-54. DOI: https://doi.org/10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
Nnonyelum ON, Anazoeze MJ, Eunice NO, et al. Multiple myeloma in Nigeria: a multi-centre epidemiological and biomedical study. Pan Afr Med J. 2015;22:292. DOI: https://doi.org/10.11604/pamj.2015.22.292.7774
Madu AJ, Ocheni S, Nwagha TA, et al. Multiple myeloma in Nigeria: an insight to the clinical, laboratory features, and outcomes. Niger J Clin Pract. 2014;17:212-7. DOI: https://doi.org/10.4103/1119-3077.127561
Nwabuko OC, Igbigbi EE, Chukwuonye II, et al. Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions. Cancer Manag Res. 2017;9:189-96. DOI: https://doi.org/10.2147/CMAR.S126136
Davies MP, Fingas S, Chantry A. Mechanisms and treatment of bone pain in multiple myeloma. Current Opinion in Supportive and Palliative Care. 2019;13:408-16. DOI: https://doi.org/10.1097/SPC.0000000000000467
Sonmez M, Akagun T, Topbas M, et al. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res. 2008;27:11-5. DOI: https://doi.org/10.1186/1756-9966-27-11
Kulak CA, Borba VC, Jorgetti V, et al. Skeletal microstructural abnormalities in postmenopausal women with chronic obstructive pulmonary disease. J Bone Miner Res. 2010;25:1931-40. DOI: https://doi.org/10.1002/jbmr.88
Poirier JL, Wurtz LD, Collier CD. Increased number of medical comorbidities associated with increased risk of presenting with pathological femur fracture in metastatic bone disease. Iowa Orthop J. 2023;43:87-93.
Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010; 21:195-214. DOI: https://doi.org/10.1007/s00198-009-1066-z
Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. Journal of Bone and Mineral Research. 2004;19:893-9. DOI: https://doi.org/10.1359/JBMR.040134
McKay LI, Cidlowski JA. Corticosteroids in the Treatment of Neoplasms. In: Holland-Frei Cancer Medicine. 6th edition. Hamilton, USA; BC Decker; 2003.
Chen SJ, Liao WC, Huang KH, et al. Chronic obstructive pulmonary disease and allied conditions is a strong independent risk factor for osteoporosis and pathologic fractures: a population-based cohort study. QJM. 2015;108:633-40. DOI: https://doi.org/10.1093/qjmed/hcv012

How to Cite

Duru, A. N., Nonyelu, C. E., Madu, A. J., Okoye, H. C., Ugwu, A. O., Anigbogu , I. O., & Muoghalu , E. A. (2024). Attributes of pathological fractures in a Nigerian myeloma cohort. Annals of Clinical and Biomedical Research, 5(2). https://doi.org/10.4081/acbr.2024.515